Eli Lilly and Company has appointed Chandan S. as Senior Director – Data Science and AI Engineering, strengthening the company’s leadership in artificial intelligence, machine learning, and advanced analytics within the life sciences sector.
Chandan brings significant industry experience across AI-driven analytics, commercial intelligence, and digital transformation initiatives. Over the years, he has built expertise in developing scalable AI platforms, leading global data science teams, and driving innovation through data-led decision-making frameworks in healthcare and life sciences.
Before joining Eli Lilly and Company, Chandan held senior leadership positions at Axtria – Ingenious Insights, where he was involved in leading data science programs focused on Generative AI, decision intelligence engines, patient analytics, and omnichannel AI orchestration. His work also included building advanced analytics capabilities designed to improve strategic and commercial outcomes within the pharmaceutical industry.
Prior to his tenure at Axtria, Chandan spent more than a decade at WNS Global Services, where he led multiple transformation initiatives across AI and machine learning, pricing analytics, natural language processing, and market access solutions for life sciences organizations. During this period, he contributed to the development of analytics-driven programs aimed at enhancing operational efficiency and commercial performance.
His professional journey also includes experience with Genpact, Thomson Reuters, and NIIT SmartServe, where he worked across research, compliance, analytics, quality management, and business process functions. Through these roles, he developed broad expertise in data analytics, enterprise transformation, and technology-enabled business solutions.
The appointment reflects Eli Lilly and Company’s continued focus on expanding its AI and data science capabilities as pharmaceutical and healthcare organizations increasingly adopt advanced technologies to improve research, commercialization, and patient engagement strategies. Chandan’s experience in combining AI innovation with large-scale analytics transformation is expected to support the company’s ongoing digital and data-driven initiatives.
With the growing role of artificial intelligence in healthcare and life sciences, leadership appointments focused on AI engineering and advanced analytics continue to gain strategic importance across the global pharmaceutical industry.
